New anti-idiotypic Affimer binders to trastuzumab

Anti-idiotypic reagents must be highly specific, sensitive and reproducible. Affimer technology meets these requirements for critical reagents in pharmacokinetic assays. Our new study highlights the development and validation of trastuzumab specific anti-idiotypic Affimer binders within a pharmacokinetic assay, showing that:

• Affimer binders to trastuzumab were identified and validated within just 3 months.
• The selected Affimer binder was entirely specific for the trastuzumab antibody target and showed comparable sensitivity to the natural ligand, HER2.
• A high level of batch-to-batch reproducibility was observed across four separate batches of Affimer protein.